Role of Free Valproic Acid Levels in a Patient with Severe Hypoalbuminemia: A Case Report

Affiliations

¹ , BSc, BSc(Pharm), ACPR, PharmD, is with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta.
² , BSc(Pharm), MSc, PhD, FNCS, is with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta.

Case Reports

Tanveer Brar et al. Can J Hosp Pharm. 2022.

. 2022 Jul 4;75(3):239-242.

doi: 10.4212/cjhp.3179. eCollection 2022 Summer.

¹ , BSc, BSc(Pharm), ACPR, PharmD, is with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta.
² , BSc(Pharm), MSc, PhD, FNCS, is with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta.

No abstract available

Conflict of interest statement

Competing interests: None declared.

Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery.
Wu R, Li K, Zhao Z, Mei S. Wu R, et al. Eur J Clin Pharmacol. 2024 Nov;80(11):1819-1828. doi: 10.1007/s00228-024-03746-x. Epub 2024 Aug 29. Eur J Clin Pharmacol. 2024. PMID: 39210212
Pharmacotherapy variability and precision medicine in neurocritical care.
Mahmoud SH, Kharouba M, Aboelezz A, Elshamy A, Gunn E. Mahmoud SH, et al. Front Neurol. 2025 Jul 18;16:1630163. doi: 10.3389/fneur.2025.1630163. eCollection 2025. Front Neurol. 2025. PMID: 40757024 Free PMC article. Review.
Physiologically Based Pharmacokinetic Modeling-Based Evaluation of Current Carbamazepine and Valproic Acid Dosing Guidelines for Pediatric Epilepsy Treatment.
van der Heijden JEM, Gijsen V, van Uden AM, de Hoop-Sommen M, Freriksen JJM, Jacobs E, Greupink R, de Wildt SN. van der Heijden JEM, et al. Paediatr Drugs. 2025 Sep;27(5):641-652. doi: 10.1007/s40272-025-00707-4. Epub 2025 Jul 2. Paediatr Drugs. 2025. PMID: 40603737 Free PMC article.

1. Abou-Khalil BW. Antiepileptic drugs. Continuum (Minneap Minn) 2016;22(1 Epilepsy):132–56. - PubMed
1. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007;64(16):2090–103. doi: 10.1007/s00018-007-7079-x. - DOI - PMC - PubMed
1. Silva MFB, Aires CCP, Luis PBM, Ruiter JPN, IJlst L, Duran M, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31(2):205–16. doi: 10.1007/s10545-008-0841-x. - DOI - PubMed
1. Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure. 2008;17(6):572–5. doi: 10.1016/j.seizure.2007.12.007. - DOI - PubMed
1. Wulff K, Flachs H, Würtz-Jorgensen A, Gram L. Clinical pharmacological aspects of valproate sodium. Epilepsia. 1977;18(2):149–57. doi: 10.1111/j.1528-1157.1977.tb04463.x. - DOI - PubMed